Treatments

Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

Early ART in HIV Possible Key to Dolutegravir Monotherapy Success

By

Dolutegravir monotherapy was noninferior to combination antiretroviral therapy (cART) in patients who started cART during primary HIV infection.

Single-Dose Tafenoquine Effective in Preventing Relapse of <i>P vivax</i> Malaria

Single-Dose Tafenoquine Effective in Preventing Relapse of P vivax Malaria

By

Compared with placebo, single-dose tafenoquine significantly lowered risk for Plasmodium vivax malaria relapse at 6 months.

Practices Vary in Treating Adult <i>Staphylococcus aureus</i> Bacteremia

Practices Vary in Treating Adult Staphylococcus aureus Bacteremia

By

Practices vary among clinicians in diagnosing and managing Staphylococcus aureus bacteremia in adults.

CP101 Designated Breakthrough Tx for Recurrent <i>C difficile</i> Infection

CP101 Designated Breakthrough Tx for Recurrent C difficile Infection

By

The FDA has granted Breakthrough Therapy designation to CP101 for the treatment of patients with recurrent Clostridium difficile.

Treating Shingles Does Not Reduce Increased Risk for Stroke

Treating Shingles Does Not Reduce Increased Risk for Stroke

By

The risk for stroke is significantly increased after the appearance of shingles, despite adequate antiviral therapy and administration of the shingles vaccine.

Sofosbuvir-Velpatasvir Safe and Effective for Some Patients With Chronic HCV

Sofosbuvir-Velpatasvir Safe and Effective for Some Patients With Chronic HCV

By

Sofosbuvir-velpatasvir administered for 12 weeks is efficacious and safe for Asian patients with chronic HCV.

Cardiovascular Disease Events and Statin Eligibility in Patients With HIV

Cardiovascular Disease Events and Statin Eligibility in Patients With HIV

By

More patients with HIV who were not recommended for statin therapy experienced cardiovascular disease events compared with a control group.

DPP-4 Inhibition May Reduce Atherogenesis in HIV

DPP-4 Inhibition May Reduce Atherogenesis in HIV

By

Treatment with sitagliptin had no effect on soluble CD14 when given to participants with virally suppressed HIV infection.

Corticosteroid Use Reduces 28-Day Mortality in Sepsis

Corticosteroid Use Reduces 28-Day Mortality in Sepsis

By

The administration of corticosteroids in patients with sepsis may be associated with significant improvement in patient outcomes.

Ledipasvir-Sofosbuvir Treatment for Chronic Hepatitis C Virus Infection

Ledipasvir-Sofosbuvir Treatment for Chronic Hepatitis C Virus Infection

By

Ledipasvir-sofosbuvir treatment for chronic HCV infection may be efficacious, safe, and tolerable for HCV genotype 1 and 4.

Study to Test Efficacy of Liposomal Amphotericin for Cryptococcal Meningitis

Study to Test Efficacy of Liposomal Amphotericin for Cryptococcal Meningitis

By

Researchers plan to conduct a study examining whether a single high dose of liposomal amphotericin with high-dose fluconazole and flucytosine is noninferior to amphotericin.

Tafenoquine Appears Safe and Effective for Prevention of Malaria

Tafenoquine Appears Safe and Effective for Prevention of Malaria

By

Chemoprophylaxis with tafenoquine is safe and effective for preventing malaria in healthy non-immune individuals challenged with blood stage P falciparum.

Antibiotic Prescribing for CAP May Differ in Pediatric Specialty Hospitals

Antibiotic Prescribing for CAP May Differ in Pediatric Specialty Hospitals

By

Compared with those at children's hospitals, children receiving CAP care at other hospital types are less likely to be treated as per national guidelines.

Antiretroviral Resistance Testing in People With HIV May Not Be Beneficial

Antiretroviral Resistance Testing in People With HIV May Not Be Beneficial

By

Antiretroviral drug resistance testing may not benefit people who have HIV, specifically in terms of mortality risk and disease progression.

Effect of HIV Pretreatment Drug Resistance on Virologic Outcomes

Effect of HIV Pretreatment Drug Resistance on Virologic Outcomes

By

Dual-class pretreatment drug resistance to first-line tenofovir/emtricitabine/efavirenz regiment may be associated with poorer virologic suppression.

Combining Corticosteroids and Antibiotics May Be Cost-Effective in CAP

Combining Corticosteroids and Antibiotics May Be Cost-Effective in CAP

By

Treating severe community-acquired pneumonia with a combination of corticosteroids and antibiotics may be a cost-effective strategy.

Voriconazole-Resistant Invasive Aspergillosis Associated With Higher Mortality

Voriconazole-Resistant Invasive Aspergillosis Associated With Higher Mortality

By

Patients with voriconazole-resistant invasive aspergillosis have a higher mortality rate compared with patients with voriconazole-susceptible infection.

Early Benznidazole Treatment Improves Outcomes in Chagas Disease

Early Benznidazole Treatment Improves Outcomes in Chagas Disease

By

Benznidazole treatment during the early phases of chronic Chagas disease infection reduced parasitemia significantly.

Influenza Point-of-Care Tests Influence Patient Outcomes

Influenza Point-of-Care Tests Influence Patient Outcomes

By

Point-of-care testing for influenza has a role persons with influenza-like illnesses, particularly in emergency departments and during influenza epidemics, but tests are not a substitute for clinical assessment.

Isavuconazole Not Noninferior to Caspofungin for Invasive Candida Infections

Isavuconazole Not Noninferior to Caspofungin for Invasive Candida Infections

By

Isavuconazole did not demonstrate noninferiority compared with caspofungin in the primary treatment of proven candidemia or invasive candidiasis.

Management of <i>Mycobacterium chimaera</i> Outbreak From Heater-Cooler Units

Management of Mycobacterium chimaera Outbreak From Heater-Cooler Units

By

There is currently a global outbreak of disseminated Mycobacterium chimaera related to the widely used surgical device LivaNova 3T heater-cooler unit contamination.

Novel <i>H pylori</i> Eradication Therapy Effective in Phase 3 Trial

Novel H pylori Eradication Therapy Effective in Phase 3 Trial

By

The ERADICATE Hp2 trial enrolled 455 dyspepsia patients at 55 sites across the US and randomized them to receive 4 capsules, 3 times daily, of either Talicia or the active comparator, for 14 days.

Topical 15% Paromomycin-Aquaphilic Effective For New World Leishmaniasis

Topical 15% Paromomycin-Aquaphilic Effective For New World Leishmaniasis

By

Treatment for cutaneous leishmaniasis caused by Leishmania braziliensis, using 15% paromomycin-Aquaphilic, was superior to a negative vehicle control.

Biologic Agents Used to Treat Patients With Psoriasis and HIV Infection

Biologic Agents Used to Treat Patients With Psoriasis and HIV Infection

By

Investigators evaluated the safety and effectiveness of conventional therapy with biologic immunosuppressive drugs to treat patients with HIV infection and psoriasis.

Re-Assessing Renal Dose Adjustments of Antibiotics: Expert Q&A

Re-Assessing Renal Dose Adjustments of Antibiotics: Expert Q&A

By

For patients with serious infectious diseases, the first 48 hours represent a critical window for antibiotic administration.

USPSTF Suggests Universal HIV Screening, PrEP for High-Risk Patients

USPSTF Suggests Universal HIV Screening, PrEP for High-Risk Patients

Screening recommended for those ages 15 to 65 years, including pregnant women.

HCV Reinfection Rates Examined Following Successful Treatment

HCV Reinfection Rates Examined Following Successful Treatment

By

In order to determine HCV reinfection rates following sustained virologic response (SVR) in the overall population as well as in PWID, the study authors analyzed data obtained from a population-based study that included >1.7 million people that were tested for HCV.

6-Week Antibiotic Treatment Effective for Spinal Surgery Site Infections

6-Week Antibiotic Treatment Effective for Spinal Surgery Site Infections

By

Six-week antibiotic treatment is sufficient for early, spinal surgery site infections.

Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis

Glecaprevir/Pibrentasvir 8-Week Regimen Evaluated in Treatment-Naïve HCV Patients With Compensated Cirrhosis

By

In EXPEDITION-8, 280 treatment-naïve HCV patients (genotypes 1, 2, 4, 5, and 6) with compensated cirrhosis were treated with Mavyret for 8-weeks; the primary efficacy measure was SVR12 rate.

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

Direct-Acting Antiviral Therapy Linked to Reduced Risk of Incident T2D in HCV Patients

By

The study compared US administrative claims data of HCV patients with ≥12 weeks of dispensed DAA therapy (N=17,848) to untreated HCV patients with follow-up data (N=108,350).

Sign Up for Free e-newsletters